During the last session, Milestone Pharmaceuticals Inc (NASDAQ:MIST)’s traded shares were 9.01 million, with the beta value of the company hitting 1.04. At the end of the trading day, the stock’s price was $2.25, reflecting an intraday gain of 11.94% or $0.24. The 52-week high for the MIST share is $2.75, that puts it down -22.22 from that peak though still a striking 50.22% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $120.05M, and the average intraday trading volume over the past 10 days was 4.17 million shares, and the average trade volume was 1.41 million shares over the past three months.
Milestone Pharmaceuticals Inc (MIST) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.40. MIST has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.2.
Milestone Pharmaceuticals Inc (NASDAQ:MIST) trade information
Milestone Pharmaceuticals Inc (MIST) registered a 11.94% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 11.94% in intraday trading to $2.25, hitting a weekly high. The stock’s 5-day price performance is 15.38%, and it has moved by 28.57% in 30 days. Based on these gigs, the overall price performance for the year is 30.06%. The short interest in Milestone Pharmaceuticals Inc (NASDAQ:MIST) is 0.88 million shares and it means that shorts have 0.62 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 77.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $10 respectively. As a result, MIST is trading at a discount of -344.44% off the target high and -344.44% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 28.21%. While earnings are projected to return -80.60% in 2025, the next five years will return 2.38% per annum.
MIST Dividends
Milestone Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Mar-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Milestone Pharmaceuticals Inc (NASDAQ:MIST)’s Major holders
Milestone Pharmaceuticals Inc insiders own 0.65% of total outstanding shares while institutional holders control 46.69%, with the float percentage being 47.00%. BLACKROCK INC. is the largest shareholder of the company, while 53.0 institutions own stock in it. As of 2024-06-30, the company held over 4.97 million shares (or 7.5135% of all shares), a total value of $6.56 million in shares.
The next largest institutional holding, with 3.26 million shares, is of RTW INVESTMENTS, LP’s that is approximately 4.9211% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $4.3 million.
Also, the Mutual Funds coming in first place with the largest holdings of Milestone Pharmaceuticals Inc (MIST) shares are Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund and SPDR INDEX SHARES FUNDS-SPDR(R) S&P(R) International Small Cap ETF . Data provided on Dec 31, 2024 indicates that Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund owns about 19.87 shares. This amounts to just over 0.04 percent of the company’s overall shares, with a $44712.0 market value. The same data shows that the other fund manager holds slightly less at 19.12, or about 0.04% of the stock, which is worth about $43013.0.
